Tekla Capital Management

Oculis S.A. raised $91M on March 3, 2023

Investors: Earlybird Venture Capital, VI Partners AG and Tekla Capital Management

Amolyt Pharma raised $137M on January 6, 2023

Investors: Intermediate Capital Group (ICG), OrbiMed Advisors, Sofinnova Partners, Sectoral Asset Management, Pontifax Venture Capital and Tekla Capital Management

Invetx raised $61M on May 10, 2022

Investors: Anterra Capital, Casdin Capital, LLC, Novo Holdings, GV, F-Prime Capital Partners and Tekla Capital Management

MoonLake Immunotherapeutics AG raised $115M on April 6, 2022

Investors: RTW Investments, LP, Asymmetry Capital Management, L.P., Surveyor Capital, Monashee Investment Management LLC and Tekla Capital Management

Arkuda Therapeutics raised $64M on February 10, 2022

Investors: Surveyor Capital, Atlas Venture, Mission BioCapital and Tekla Capital Management

Endeavor Biomedicines raised $101M on February 7, 2022

Investors: Omega Funds, Revelation Partners, Longitude Capital, T. Rowe Price, Avidity Partners, Perceptive Advisors and Tekla Capital Management

Quell Therapeutics raised $156M on November 29, 2021

Investors: SV Life Sciences, Syncona Limited, Monashee Investment Management LLC, JEITO, British Patient Capital, Ridgeback Capital Management LLC, Point72 Asset Management and Tekla Capital Management

Arbor Biotechnologies raised $215M on November 9, 2021

Investors: TCG X, Tao Capital Partners, Surveyor Capital, T. Rowe Price, Section 32, Vertex Pharmaceuticals, Temasek, Ridgeback Capital Management LLC, Woodline Partners LP and Tekla Capital Management

Parthenon Therapeutics raised $65M on November 3, 2021

Investors: Section 32, Breakout Ventures, KdT Ventures, Northpond Ventures and Tekla Capital Management

ReCode Therapeutics raised $210M on October 21, 2021

Investors: Sanofi Ventures, NS Investment, -, OrbiMed Advisors, Vida Ventures, LLC, Osage University Partners (OUP), MPM Capital and Tekla Capital Management